

#### **CDISC Controlled Terminology**

Presented by Dr. Erin Muhlbradt, PhD With Special Guest: Dr. Jordan Li, PhD

10.03.2023






#### **Controlled Terminology P55 Publication and P56 Public Review**

cdisc

Dr. Erin Muhlbradt, Clinical/Biomedical Information Specialist, MSC Inc., a Guidehouse company

Dr. Jordan Li, Clinical/Biomedical Information Specialist, MSC Inc., a Guidehouse company

10.03.2023



# **Question & Answer**

- 1. 'Panelist': Question
- OR
- 1. 'Presentation': Question

#### Examples:

- 1) What should be supported by ADaM datasets?
- 2) Jack: Is there a limit to the number of variables that can be in ADSL?

#### **Content Disclaimer**


1. All content in this presentation is for education and information only. References to any specific commercial product, process, service, or corporation are also for information only, and do not constitute endorsement, recommendation, or favoring by CDISC or the CDISC community.

# Agenda

#### 1. Package 55 Publication Release (2023-09-29)

- Changes post-public review
- 2. <u>Package 56 Public Review</u> (2023-09-22 to 2023-10-20)
  - New Additions
  - Changes to existing
- Feedback requested CT publication cadence

#### 1. Questions



#### **Controlled Terminology Package 55 Publication**

2023-09-29

#### **Controlled Terminology Publication Schedule**

**CDISC Terminology Publication Schedule** 

Package Number	Team Cutoff (requests must be received at least two months before this date)	Start Date (1 wk from Team Cutoff)	Public Review Closed Date (4 wks/30 days)	Final Changes to NCI EVS (4 wks)	Publication Date (6 wks)		Codelists to be Included		
51	6/10/2022	6/17/2022	7/15/2022	8/19/2022	9/30/2022	Biospec	Cell Pheno	Define-XML	Devices
51						General	Genomics	Lab	Microbio/Immu no
51						Oncology	Protocol Entities	SDTM Domain	SEND
51						Unit			
52	9/16/2022	9/23/2022	10/21/2022	11/18/2022	12/16/2022	Cell Pheno	Define-XML	Define-XML	General
52						Glossary	Lab	Microbio/Immu no	Oncology
52						Protocol Entities	SEND	Unit	
53	12/9/2022	12/16/2022	1/20/2022	2/17/2023	3/31/2023	Biospec	Cell Pheno	General	Lab
53						Microbio/Immu no	Protocol Entities	SEND	Unit
54	3/17/2023	3/24/2023	4/21/2023	5/19/2023	6/30/2023	ADaM	Biospec	Cell Pheno	CV
54						Define-XML	General	Lab	Microbio/Immu no
54						MRCT	Oncology	РК	Protocol Entities
54						SEND	Unit		
55	6/16/2023	6/23/2023	7/21/2023	8/18/2023	9/29/2023	Biospec	Cell Pheno	Devices	ECG
55						General	Genomics	Lab	Microbio/Immu no
55						MRCT	Oncology	PK	Protocol Entities
55						Unit			
56	9/15/2023	9/22/2023	10/20/2023	11/17/2023	12/15/2023	Biospec	Cell Pheno	Define-XML	ECG
56						CDISC Glossary	Lab	General	Genomics
56						Microbio/Immu no	MRCT	Oncology	SDTM Domain
56						SEND	Unit		
57	12/8/2023	12/15/2023	1/12/2024	2/9/2024	3/29/2024				
57									
58	5/31/2024	6/7/2024	7/5/2014	8/2/2024	9/27/2024				
58									
59	12/13/2024	12/20/2024	1/17/2025	2/14/2025	3/28/2025				



9/19/2023

Dates in red are planned and may be adjusted slightly.

# Controlled Terminology Package 55 Publication Release

- Updates to DDF, Protocol Entities, SDTM, and SEND Terminology
- Other Project Support:
  - COVID-19 v2.0 TAUG
  - Rare Diseases TAUG
  - DDF USDM (Phase 2)



#### Significant Changes Post-Public Review

- Cell Phenotyping:
  - <u>CPTEST/CD</u>: Submission value 'OX40X' updated to 'CD134X' for consistency in naming.
- Laboratory:
  - <u>MITS/CD</u>: Submission value 'Adequate Surgical Margin Indicator' updated to 'Adequate Surgical Margins Indicator' for consistency in naming.
- General:
  - <u>PROCEDUR:</u> Removed the double space from the CDISC submission value 'AUTOLOGOUS STEM CELL TRANSPLANT'



#### Significant Changes Post-Public Review

Other, less significant changes\* also made in:

Microbiology-Immunology

No post-public review changes made to:

- Biospecimens
- CP
- Device
- ECG
- Genomics
- Lab
- Oncology
- PK
- Protocol
- UNIT

\*Please note that changes have been made to the terms proposed in the public review documents (edits to proposed definitions, additions of synonyms, etc.) that were not covered in previous slides. Please refer to published CT as the definitive source for terminology.



#### P55 Terminology Products Updates


- <u>Updates on CDISC.org:</u>
  - Updated Codetable mappings:
    - DD, EG, IS, RE, RP, SC, and TS
  - Unit-UCUM\_Codetable
  - Controlled\_Terminology\_Requests\_Denied\_P55
  - Paired Codelists product for SDTM and SEND
  - Terminology Publication Schedule
  - Terminology Development Rules documents:
    - QRS
    - IS
    - MB and MS
    - Lab, Unit, and MI




#### QRS Controlled Terminology Package 55 Publication Release

- 1 new CAT value
  - FACIT-SEARCHABLE ITEM LIBRARY PEDIATRIC
- 1 new paired TEST/TESTCD codelists
  - QS-FACIT-Searchable Item Library Pediatric (FSLPTN/FSLPTC)





2023-09-22 to 2023-10-23



cdisc

https://www.cdisc.org/public-review/controlled-terminology-package-56

# Public Review Comment Submission – Process Update!

- Two pieces of information are CRITICAL to getting your review comment seen by the CT teams:
  - Component identifies the name of the specific PR file relevant to the comment.
  - Package (56) identifies the package number that is relevant to the comment.
- Failure to fill in this information may delay resolution of your comment.

0	Create Issue	Select Template 👻 🗘 Configure Fields
С	All fields marked with an asterisk (*) are required	*
?	Project* 🛛 Controlled Terminology (CT)	
0	Issue Type* 🚺 Improvement 🔹 🕐	
0	Summary*	
0	Component/s Start typing to get a list of possible matches or press down t	▼ to select.
0	Package None V	
0	Fix Version/s 34 35 Description 36	
0	$\begin{array}{c ccc} \text{B} & I & \underline{\cup} & \underline{\wedge} & \overset{\circ}{\rightarrow} & & & & \\ \hline 38 \\ 39 \end{array}$	/ ∭~ ≔ ≔ ⊚~ +~ *
0	40 41 42	
	43 44	
0	45 46 47 Text	
0	Review Period 50	
T	51	Create another Create Cancel



- ADaM Team
  - No new term or changes to existing to report this quarter
  - No denied requests



#### • Biospecimens Team

- New Terms Added to Existing Codelists:
  - BEDECOD; BSTEST-CD
- No changes to published terms
- No denied requests



- CDASH Team
  - No new term or changes to existing to report this quarter.
  - No denied requests



- Cell Phenotyping Team
  - No new terms added to existing codelists
  - No denied requests
  - 10 changes to published terms; 3 are significant
    - CPTEST-CD
      - C189412 Update CPTEST from 'TLym Cytx Naive Sub/TLymC' to 'TLym Cytx Naive Sub/TLym Cytx'
      - C189407 Update CPTEST from 'TLym Cytx Cen Mem Sub/TLymC' to 'TLym Cytx Cen Mem Sub/TLym Cytx'
      - C189409 Update CPTEST from 'TLym Cytx Eff Mem Sub/TLymC' to 'TLym Cytx Eff Mem Sub/TLym Cytx'

\*\*Changing denominator <u>TLymC</u> to <u>TLym Cytx</u> to make consistent with other cell count terms of this type.



- CV Team
  - No new term or changes to existing to report this quarter.
  - No denied requests.



- Medical Devices Team
  - No new term or changes to existing to report this quarter.
  - No denied requests.



- DDF Team
  - No new term or changes to existing to review this quarter.
  - No denied requests.



- Define-XML Team
  - No new terms this quarter
  - No denied requests.
  - 2 changes to existing; neither are significant (definition updates)



- ECG Terminology Team:
  - New Terms Added to Existing Codelists:
    - HESTRESC
  - Update to ECG Codetable Mapping File
  - No denied requests



- General Terminology Team:
  - New Terms Added to Existing Codelists:
    - DATEST-CD; DIR; FRM; LOC; NCOMPLT; NVTEST-CD; PROCEDUR; PROTMLST; RETEST-CD; ROUTE
  - 18 changes to published terms; 5 are significant
    - See next slide
  - Updates to Codetable Mapping Files:
    - DS\_Codetable\_Mapping
    - RE\_Codetable\_Mapping
    - SC\_Codetable\_Mapping
    - TS\_Codetable\_Mapping
  - Denied Requests added to Denied Requests spreadsheet



- General Terminology Team:
  - 5 significant changes to existing terms
    - SCTEST-CD:
      - C102713 Source Case Investigation/SRCCSINV is being retired from the codelist
        - This SCTEST was published in error during Ebola v1.0 TAUG development. As per the published Ebola TAUG v1.0, this value is modeled as a --CAT value instead of a SCTEST-CD value.
      - C102625 Contact Investigation/CNTCINV is being retired from the codelist
        - Replace C102625 with a CNEW term in P56; the purpose of this as modeled in the TB TAUG is as an indicator (Y/N) question. The Update NCI C-code, CDISC Submission Value, CDISC Synonyms, CDISC Definition, and NCI Preferred Term.
    - SEX:
      - C45908 submission value UNDIFFERENTIATED is being changed to INTERSEX. 'UNDIFFERENTIATED' is antiquated terminology.



- Genomics Terminology Team:
  - No new term or changes to existing to review this quarter.
  - No denied requests.



- CDISC Glossary Team
  - 9 new terms proposed to be added this quarter:
    - dose-escalation trial
    - screening (period)
    - blood draw
    - eligibility criteria
    - infusion
    - investigational device
    - compendial name
    - active substance
    - protocol title
  - 45 Changes to Existing terms
  - 18 new source additions
  - No denied requests.



- Laboratory Terminology Team
  - New Terms Added to Existing Codelists:
    - LBANMET; LBTEST-CD; METHOD; MITS-CD
  - 35 changes to published terms; 12 are significant
  - Denied Requests added to Denied Requests spreadsheet.



- Laboratory Terminology Team
  - Significant Changes to Existing Terms
    - MITS-CD
      - The team is proposing to remove the following MITS-CD values:
        - C103368/CD20 Retire from codelist and replace with Membrane Spanning 4-Domains A1/LEU1 (new in P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE CELL
        - C103370/CD56 Retire from codelist and replace with Neural Cell Adhesion Molecule 1/NCAM1 (new with P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE CELL
        - C103809/CD3 Retire from codelist and replace with CD3 T-Cell Marker/CD3TCM (new with P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE CELL
        - C103810/CD4 Retire from codelist and replace with T-Cell Surface Antigen T4/Leu-3 / LEU3 (new with P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE CELL
        - C103811/CD8 Retire from codelist and replace with T-Cell Surface Glycoprotein CD8/CD8 (new with P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE CELL
        - C156544/CD68 Retire from codelist and replace with Scavenger Receptor Class D, Member 1/SCARD1 (new with P56). Use published MITSTDTL=POSITIVE CELL COUNT or MITSTDTL=PERCENT POSITIVE



CELL

- Laboratory Terminology Team (Units of Measure)
  - New Terms Added to Existing Codelists:
    - UNIT
  - 2 changes to published terms; none significant
  - Denied Requests added to Denied Requests spreadsheet.



- Microbiology-Immunology Terminology Team
  - New Terms Added to Existing Codelists:
    - ISBDAGT; ISFTSDTL; ISTEST-CD; MICROORG
  - 377 Changes to existing term; 374 are significant
  - Updates to Codetable Mapping Files:
    - IS Terminology Mapping Codetable
  - Updates to Terminology Team Development Rules Documents:
    - IS
  - Denied Requests added to Denied Requests spreadsheet.



- MRCT Plain Language Glossary
  - 8 new terms

Search Glossary. Q HOME ABOUT ~ GLOSSARY WORDS	Clinical Research	MULTI-REGIONAL CLINICAL TRIALS THE MICT CENTER of BIOGRAM AND WORKERS HOSPITAL and HARVARD					
<section-header><section-header><section-header><text><text><text><text><text></text></text></text></text></text></section-header></section-header></section-header>	UDICATION CONTACTION CONTACTICON	KT US					
The images on this site are not for distribution. All content may be shared for non-commercial purposes and credited to MRCT Center.							



Footer Text

https://mrctcenter.org/clinical-research-glossary/

- Oncology Terminology Team:
  - New Terms Added to Existing Codelists:
    - ONCRTS-CD; TUTEST-CD; TRTSET
  - New Codelist
    - DPETSCRS: Response values for TRTEST/CD = FDPL5PS/FDG PET Lymphoma 5PS Score
  - No Changes to existing terms
  - Codetable Mapping File Updates
    - TU\_Codetable Mapping
    - TR\_Codetable Mapping
    - RS\_Onc\_Codetable Mapping
    - RS\_IWC\_HALLEK\_CLL\_2018
  - Denied Requests added to Denied Requests spreadsheet.



- PK Terminology Team
  - No new terms or changes to existing.
  - Denied Requests added to Denied Requests spreadsheet.



- Protocol Entities Terminology Team
  - No new term or changes to existing to review this quarter.
  - No denied requests.



# Controlled Terminology Package 56 Public Review

- QRS Terminology Team
  - No files for public review
  - Denied Requests added to Denied Requests spreadsheet.



# Controlled Terminology Package 56 Public Review

- SDTM Domain Terminology Team
  - New Terms Added to Existing Codelists:
    - DOMAIN
  - 1 Change to existing; not significant (definition update)
  - No Denied Requests.



# Controlled Terminology Package 56 Public Review

- SEND Terminology Team
  - New Terms Added to Existing Codelists:
    - GVTEST-CD; NONNEO; SBCSND-CD; SPEC
  - 5 Changes to existing terms; 4 are significant
    - NULLFLAV -> The following terms are being proposed to be retired from the Null Flavor codelist due to lack of use in Non-Clinical setting.
      - C42885/DERIVED
      - C150902/UNENCODED
      - C17649/OTHER
      - C50913/INVALID
  - Denied Requests added to Denied Requests spreadsheet.



# Scope Change for LB/MB/IS and Impact on Controlled Terminology in P56

40



# The IS Domain Scope Update for the SDTMIG v3.4

- The current IS domain in the SDTMIG v3.4 is designed to collect data pertaining to *specimen-based* assessments that measure the "presence, magnitude and scale of the immune response upon <u>any</u> antigen stimulation or encounter".
- This effectively expands the scope of the IS domain from the pervious SDTMIG versions (3.2 and 3.3) where the IS domain was limited to "assessments that describe whether a (study) *therapy* provoked/caused/induced an immune response."
- Per the SDTMIG 3.4, the *antigen of interest* in the above definition may be (but is not limited to), drug/test article (i.e., study/non-study therapy), allergen, microorganism (e.g. bacteria, viruses, fungi, parasites, etc.), self-antigen (autoantigen), and others, that may stimulate a host immune response.
- The current IS domain definition is also more inline with the scientific/medical definition of "immunogenicity assessment" and is well-accepted by the scientific community.
- Both humoral (antibody-mediated) immune response testing + cell-mediated immune response testing are in scope.



# 1: Domain and variable level structure limitation for LB/MB/IS

Prior to the SDTMIG v3.4, most specimen-based, immune response testing data had been mapped to the MB and LB domains which were not built to collect and model complicated experimental designs and biological processes, which yield complicated data. These domains do NOT have the sufficient structure and standard variables to support the meaningful and <u>consistent</u> representation of such data.

As a result, various supplemental qualifiers had been created and used to map key information in both LB and MB. This also resulted in too much information being mapped and pre-coordinated into the LB/MBTEST-TESTCD variables, and therefore overloading the –TEST and TESTCD variables.



### 2: Multiple different SDTM Findings domains were used to represent specimen-based immune response testing data

The prior IS domain scope defined by the SDTMIG v3.2/v3.3 limited its use to ONLY collection of "study therapy"-induced immune response testing data, this led to "baseline" immune response testing data *prior to study treatment exposure* having to be mapped to a different domain. Compounding on this problem, the <u>same</u> pre-study treatment exposure data would have to be mapped to different domains depending on the version of the SDTMIG used and the study types.



# Rationales and the Problems that Led to the IS Domain Update for the SDTMIG v3.4

- 1. LB/MB/IS in the IGv3.2 and v3.3: significant overlap of domain scope and data mapping between the three domains. Scope definition and demarcation between the three domains were unclear. As a result, multiple different SDTM Findings domains were used to represent specimen-based immune response testing data.
- 2. Domain and variable level structure limitation for LB/MB/IS.
- 3. General disagreement and confusion over the prior narrow definition of the IS domain what's considered as therapy?
- 4. Multiple SDTM Classes are utilized to model systemic vs. localized immune responses.

For more information and an in-depth analysis on the changes made to LB, MB and IS, refer to this **Knowledge Base Article** on <u>www.cdisc.org</u>: <u>https://www.cdisc.org/kb/articles/domain-scope-update-sdtmig-v3-4-development-history-and-difficulties-standardizing</u>



### More Information on IS Domain Representation of Immunogenicity Data in the SDTMIG v3.4

- Pubic Webinar: LB, MB & IS Domain Scope Changes for the SDTMIG v3.4 and Impact on Controlled Terminology
- <u>https://www.cdisc.org/event</u> <u>s/webinar/lb-mb-domain-</u> <u>scope-changes-sdtmig-v3-</u> <u>4-and-impact-controlled-</u> <u>terminology</u>
- Introduction on new IS domain standard variables, MB and IS domain scope changes, new examples, updates to examples in the published TAUGs, and impact on CT, etc.



Education Webinar\_LB-MB-IS Scope Change and CT Imapact\_2023-06-22\_updated.pdf



### Impact on LB/MB/IS Controlled Terminology

The change in the IS domain scope will result in the deprecation of approximately 800+ antibody TEST and TESTCD values from both the Lab and Microbiology domains, and instead, they will be remodeled in the IS domain, using IS domain standard variables including but are not limited to: ISTEST-CD, ISBDAGNT (Binding Agent), and ISTSTDTL (Test Detail).

This announcement was made since December 2022, and the relevant information has been included in every public review package until P55 (September 2023).

In Package 56 (December 2023), we will:

- Deprecate 374 existing MBTEST-CD terms.
- Deprecate 492 additional existing LBTEST-CD terms.
- There changes to existing terms are now out for public review/comment.



# Hedging the Impact of the Changes – CDISC Education and Tools

Tools *already published* on <u>www.cdisc.org</u> to prepare for the transition:

- 1. A <u>Knowledge Base Article</u> that provides in-depth analysis and explanation on the difficulties and problems that led to the LB/MB/IS domain scope updates and the changes made to these domains in the SDTMIG v3.4.
- 2. A <u>Codetable Mapping</u> file that shows how *every* deprecated code from the LB/MB domains will be re-modeled and mapped to the IS domain new standard variables.
- 3. <u>Standards Development and CT Rules</u> documents are published for IS and MB.
  - Contain <u>FAQs</u> for most common and difficult user inquiries on where data should be mapped are published.
- 4. Webinars for public education:
  - Quarterly CT webinars.
  - Introduction and Office Hours education webinars (June 22, 2023 and Q2-3, 2024).
  - CDISC Interchange presentation.

\*Most importantly, these changes had been communicated to the FDA for review and feedback.



## **IS Terminology Codetable Mapping File**

The deprecated LB and MB terms will be remapped to IS. The mapping can be found in the **IS Terminology Codetable Mapping File**, which helps users to:

- Assign the existing terms (which are going to be deprecated) from LB and MB to IS.
  - Update dictionary, develop systems and programs in preparation for the SDTMIG v3.4 adaptation.

#### Traceability!!

- Al	A	В	C	U	E	ŀ	G	Н		J	К	
1	C-Code	MB TEST Terms for Deprecation Microbiology Test Name (codelist code = C120528)	C-Code (Concept Code)	When Varaible = ISTEST Immunogenicity Specimen Assessments Test Name (ISTEST) (codelist code = C120526)	C-Code (Concept Code)	When Varaible = ISBDAGNT Microorganism (MICROORG) (codelist code = C85491)	C-Code (Concept Code)	When Varaible = ISBDAGNT Binding Agent for Immunogenicity Tests (ISBDAGT) (codelist code = C181169)	C-Code (Concept Code)	When Varaible = ISTSTDTL Immunogenicity Specimen Test Details (ISFTSDTL) (codelist code = C189267)	Additional Notes	
183	C130097	Mucor racemosus IgA Antibody	C187776	Allergen-induced IgA Antibody	C187915	MUCOR RACEMOSUS						
184	C166022	Mucor racemosus IgE AB RAST Score	C181398	Allergen-induced IgE Antibody	C187915	MUCOR RACEMOSUS			C189493	RAST Score		
185	C130096	Mucor racemosus IgE Antibody	C181398	Allergen-induced IgE Antibody	C187915	MUCOR RACEMOSUS						
186	C166018	Mucor racemosus IgG AB RAST Score	C187777	Allergen-induced IgG Antibody	C187915	MUCOR RACEMOSUS			C189493	RAST Score		
187	C130098	Mucor racemosus IgG Antibody	C187777	Allergen-induced IgG Antibody	C187915	MUCOR RACEMOSUS						
188	C130099	Mucor racemosus IgG4 Antibody	C187778	Allergen-induced IgG4 Antibody	C187915	MUCOR RACEMOSUS						
189	C139086	HCV Antibody Signal/HCV Antibody Cutoff	C187780	Microbial-Induced Anlibody	C14312	HEPATITIS C VIRUS			C198277	SIGNAL/CUTOFF RATIO	The modeling for this type of test has changed, SIGNAL/CUTOFF is mapped to ISTSTDTL. The CDISC MBIS team will no longer create antibody target-specific, - precoordinated signal/cutoff tests.	
190												
4	ReadMe - Timeline ReadMe - How to Read this DOC LB to IS Mapping_2023-09-29					MB to IS Mapping_2023-09-29 ReadMe - New Te 🔶 🗄 🕻						

LB to IS Mapping; MB to IS Mapping show existing LBTESTs and MBTESTs to IS domain variables mapping.



### **IS Terminology Codetable Mapping File**

The IS Terminology Codetable Mapping file can also be accessed from the: https://www.cdisc.org /standards/terminolo gy/controlledterminology

- In the Supplemental Files section.
- Under the
  Codetable
  Mapping File tab.

NCI FTP Links	Resources	Rules	Codetable Mapping Files	Unit-UCUM Mapping File		
Controlled Terminology consists of question (e.g., Variables, TESTs and PARMs) and answer(e.g., respor as codelists and are published alphabetically in the Controlled Terminology publication.						
The terms within these codelists may have relationships to other terms within other codelists. For insta responses located in the EGSTRESC codelist that constitutes a subset of the EGSTRESC codelist. Anothe measure that are valid for the numeric responses to that VSTEST. These relationships are not readily app						
different_Contro	lled Terminolog	y codelist	0,	Codetable Mapping Files based ovide human and machine-read are for clinical use only.		
The Controlled Terminology teams will continue to update these files as new Terminology is published, interested in seeing specific content developed, please submit the request through the <b>New Term Requ</b> electronically consumable formats of this content to be published out of <b>CDISC Library</b> .						
Note: 2023-01-24: The SEND codetable mapping file has not been updated since CT Package 43. The submission to regulatory authorities. The file will be removed effective May, 2023.						
DD Codetable						
DS Codetable						
CV Codetable						
ECG Codetable						
GF Codetable						
GI Codetable						
IG Codetable						
IS Codetable						



## **Rules for Immunogenicity Testing File**

CDISC CONTROLLED TERMINOLOGY RULES: Immunogenicity Specimen (IS) Test Code/Name, Binding Agent for Immunogenicity Assessments, and Microorganism Codelists

16 December 2022

New standard variables were developed and introduced for the IS domain in the SDTMIG v3.4 to:

- Meet the urgent need for clear and consistent representation of specimen-based, immune response testing data.
- Resolve the long-standing issue of overloading the --TEST/--TESTCD variables.

New variables added to the IS domain, in the SDMTIG v3.4 and SDTM v2.0 are the following:

- MSCBCE (Molecule Secreted by Cells), this variable is restricted to the IS domain.
- BDAGNT (Binding Agent), TSTCND (Test Condition), and CNDAGT (Test Condition Agent) are used in IS, LB and Cell Phenotyping (CP) domains.
- TSTOPO (Test Operational Objective) is used in both the LB and IS domains.

More information, variable definition/scope/usage/rules on the above new IS domain standard variables can be found in the "**Rules for Immunogenicity Test**" document, which also contains IS controlled terminology and CT codelists naming and development rules.



### **Rules for Immunogenicity Testing File**

- If the MB/IS team gets the same or similar questions more than 3 (give or take) times, it will be added to the FAQ section of the IS Rules Doc.
  - Note this also applies to the MB/MS Rule Document.
- This sections contains a lot of "where do I map my data? LB vs IS? MB vs IS?" type of questions and answers, pls make sure to have a look.

#### GENERAL FAQ

Question 1: Why are antibody tests deprecated from LB and MB and are reassigned to IS, per the SDTMIG v3.4?

#### Answer:

Antibody tests are considered as humoral immune responses and are in scope for the IS domain per IG3.4. They should be represented by a single IS domain, regardless of study types or pre- vs. post-study therapy exposure.

For more details, refer to the Knowledge Base Article on <u>www.cdisc.org</u>, <u>IS Domain Scope Update for the SDTMIG v3.4: A</u> Development History and the Difficulties of Standardizing Complicated Biological Processes

**Question 2**: Where should I map my cytokine and complement protein testing data, such as the Interferon Gamma (IFN- $\gamma$ ) detection/quantification test? They are also considered as immune response related testing. I see complement proteins and IFN- $\gamma$  as published values in LBTEST-CD, should they be mapped to LB or IS?

#### Answer:

Our team gets this question very often, as the majority of the tests in IS had once been assigned to, and collected by LB per the SDTMIG 3.2. Generally speaking, a test is mapped to LB, if it is a part of a "routine urine or blood, standard of care and safety related testing" - this means one is *only typically* interested in the analyte's presence/absence, quantity, and whether or not the result is within the normal range (if not within normal range, it may need flagging). In a grossly simplistic (but true) view, the lab domain is not built to handle anything that requires complicated biological testing, it doesn't have the standard variables to support such data mapping (this also in part, contributes to the development of newer specimen-based domains, such as CP, GF, MB, MS, IS, etc.).

Coming back to IS vs. LB, users may find some specimen-based, immune response related tests in **<u>both</u>** LB and IS, below is the general distinction:

- A cytokine (or other similar) test is mapped to the LB domain, if it is a part of a "routine urine or blood, standard of care and safety related testing" - this means one is typically *only* interested in the cytokine's presence/absence, quantity, and whether



## **Rules for Immunogenicity Testing File**

The Rules for Immunogenicity Testing file can also be accessed from the: https://www.cdisc.org /standards/terminolo gy/controlledterminology

- In the Supplemental Files section.
- Under the Rules tab.

Supplemental	Files								
NCI FTP Links	Resources	Rules	Codetable Mapping Files						
Rules for all code	Rules for all codelists								
Rules for ADaM	Rules for ADaM								
Rules for Genom	Rules for Genomics								
Rules for Immun	Rules for Immunogenicity Specimen Tests								
Rules for Lab, Ur	nit and MI		_						
Rules for Microbiology Rules for Oncology									
							Rules for PK		



# For Users Who are Implementing/Submitting Under the SDTMIG v3.2/v3.3 – Other Recommendations

Many CDISC users are still using SDTMIG v3.2/v3.3 for whom applications and dictionaries are not yet built or equipped to implement SDTMIG v3.4:

- Per the SDTMIG 3.4, antigen-stimulated immune response testing data should be mapped to the IS domain only. Therefore, the MB/IS CT team will NO LONGER control, develop or publish new antibody terms, or other specimen-based, cell-mediated immune response testing terminology in the LB and MB domains from this point on.
- Users who are implementing/submitting under the SDTMIG v3.2/v3.3 should consider adding controlled terminology for antibody testing, or other specimen-based, immunogenicity tests as **extensible values** to LBTEST-CD and/or MBTEST-CD codelists, if immune response testing data are still mapped to LB/MB, following the rules set by the SDTMIG v3.2/3.3.

The MB/IS team still encourage users to submit their pre-coordinated **new antibody, or cell-mediated immune testing** term requests to the team, so the MB/IS team can map the term to the IS domain, according to the rules set by the SDTMIG 3.4. The mapping recommendation for the **new antibody/cell-mediated tests** can also be tracked and will also be published in the <u>IS Terminology Codetable Mapping File</u> quarterly and will be available to all users.



## Announcement: CDISC Terminology Publication Cadence

**Currently** -> CDISC publishes updates to CDISC terminology on a <u>quarterly</u> schedule: March, June, September, December

**To be Implemented ->** CDISC leadership is changing the publication cadence for CDISC Controlled Terminology to <u>biannual</u> <u>releases (twice per year)</u>: March and September

• CDISC is also considering mechanisms by which draft terminology can be made available to the user community.

\*CDISC is currently interested in receiving feedback on this proposal!

Feedback can be sent to Erin Muhlbradt (muhlbradtee@mail.nih.gov)





To the amazing and dedicated CDISC Controlled Terminology Team members and reviewers, YOU are the heart and soul of CDISC terminology!



# **CDISC Membership**

#### **Become a Member!**

Join 500+ member organizations that contribute to bringing clarity to data.

#### Already a Member?


Thank you! It is our members' support which enables us to develop standards, keeping it free and accessible to all.



Email: membership@cdisc.org








# If you are interested in contributing to any of the CDISC Terminology initiatives, please contact us...

Erin Muhlbradt, <u>muhlbradtee@mail.nih.gov</u> OR https://www.cdisc.org/volunteer

<u>CDISC New term request form:</u> <u>https://ncitermform.nci.nih.gov/ncitermform/?version=cdisc</u>





# Q&A

## **CDISC Education: Upcoming** Learning Opportunities

Bernard Klinke



# Thank you for your attendance and support of CDISC!

